CorMedix Inc. (NASDAQ:CRMD) shares are rising on Thursday after the company reported strong second-quarter results. The broader market was also slightly higher, with S&P 500 futures up 0.2%.
The biopharmaceutical company reported adjusted earnings of 29 cents per share, topping the 25-cent consensus estimate. Revenue more than doubled year over year to $101.9 million, beating the $95.6 million consensus.
Revenue included $66.1 million from DefenCath and $35.8 million from the acquired Melinta portfolio. DefenCath sales rose year over year, driven largely by the onboarding of a large dialysis organization in mid-2025.
Adjusted EBITDA jumped to $58.7 million from $22.4 million a year earlier.
CorMedix Advances REZZAYO Expansion Plans
